Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

In this randomized study, the addition of lixisenatide, a glucagon-like peptide 1–receptor agonist, to usual care in patients with type 2 diabetes and a recent cardiovascular event did not alter the rate of subsequent major cardiovascular or other serious adverse events. Randomized trials involving...

Ausführliche Beschreibung